Counterweight Ventures LLC lifted its stake in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 8.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,073 shares of the biopharmaceutical company’s stock after acquiring an additional 1,971 shares during the quarter. Counterweight Ventures LLC’s holdings in Bristol-Myers Squibb were worth $1,083,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently made changes to their positions in the stock. Chris Bulman Inc bought a new stake in shares of Bristol-Myers Squibb in the second quarter worth approximately $48,000. Mosley Wealth Management boosted its holdings in shares of Bristol-Myers Squibb by 11.8% in the second quarter. Mosley Wealth Management now owns 6,937 shares of the biopharmaceutical company’s stock worth $288,000 after buying an additional 730 shares during the last quarter. Illinois Municipal Retirement Fund boosted its holdings in shares of Bristol-Myers Squibb by 27.2% in the second quarter. Illinois Municipal Retirement Fund now owns 769,703 shares of the biopharmaceutical company’s stock worth $31,966,000 after buying an additional 164,565 shares during the last quarter. Commonwealth Retirement Investments LLC bought a new position in Bristol-Myers Squibb in the second quarter worth approximately $1,742,000. Finally, New York Life Investment Management LLC boosted its stake in shares of Bristol-Myers Squibb by 1.0% during the 2nd quarter. New York Life Investment Management LLC now owns 321,185 shares of the biopharmaceutical company’s stock worth $13,339,000 after acquiring an additional 3,261 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.
Bristol-Myers Squibb Stock Down 2.2 %
BMY opened at $48.70 on Friday. The firm has a 50-day simple moving average of $45.95 and a two-hundred day simple moving average of $46.58. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.42. The company has a market capitalization of $98.72 billion, a PE ratio of -15.71, a price-to-earnings-growth ratio of 12.92 and a beta of 0.46. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86.
Bristol-Myers Squibb Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Friday, July 5th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.93%. The ex-dividend date was Friday, July 5th. Bristol-Myers Squibb’s payout ratio is -77.42%.
Wall Street Analysts Forecast Growth
BMY has been the subject of several analyst reports. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Jefferies Financial Group upped their price objective on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research note on Wednesday, August 28th. TD Cowen upped their price objective on Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a research note on Monday, August 12th. Barclays upped their price objective on Bristol-Myers Squibb from $41.00 to $42.00 and gave the stock an “underweight” rating in a research note on Thursday, August 22nd. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research note on Tuesday, July 23rd. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $54.67.
Get Our Latest Research Report on BMY
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Articles
- Five stocks we like better than Bristol-Myers Squibb
- Using the MarketBeat Dividend Yield Calculator
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- How to Invest in Insurance Companies: A Guide
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- Are Penny Stocks a Good Fit for Your Portfolio?
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.